Navigation Links
Atrium Announces the Publication of the COBEST Trial by the Journal of Vascular Surgery
Date:9/29/2011

HUDSON, N.H., Sept. 29, 2011 /PRNewswire/ -- Atrium Medical Corporation today announced the publication of the COBEST Trial by the Journal of Vascular Surgery.  COBEST (Covered Versus Balloon Expandable Stent Trial) was an independent, landmark, prospective, multi center, randomized, controlled clinical trial that has demonstrated that Atrium's proprietary balloon expandable covered stent technology is superior to traditional bare metal stents for the treatment of aorto-iliac disease.  The journal article, "A comparison of covered vs bare metal stents for the treatment of aorto-iliac occlusive disease" is currently in press and is also available on-line at the publisher's websites, www.elsevier.com or www.sciencedirect.com .

COBEST was the first prospective head-to-head comparison of Atrium's Vascular V12 balloon expandable covered stent versus bare metal stents (BMS) for the treatment of a specific type of Peripheral Arterial Disease (PAD) known as aorto-iliac occlusive disease.  The study's principal investigator, Professor Patrice Mwipatayi, M.D., is head of vascular surgery at Royal Perth Hospital in Perth, Australia.

COBEST has demonstrated that in TASC B, C, and D iliac lesions, patients implanted with Atrium's Advanta V12 were more likely to remain free from binary restenosis and had fewer reinterventions than patients with bare metal stents implanted.  Upon sub-analysis, Dr. Mwipatayi and the other co-investigators have concluded that Atrium's Vascular V12 demonstrated the greatest benefit in patients with more complex disease (TASC C & D lesions).  There were significantly lower restenosis rates, significantly lower target vessel revascularization (TVR) rates, significantly improved ABI's, and, when these more difficult TASC C & D lesions were analyzed, lower occlusion rates were observed at twelve and eighteen months compared to BMS.  

In this study, Atrium's Vascular V12 has demonstrated higher long term patency and improved clinical outcomes compared to BMS.  COBEST was an independent investigator initiated study; Atrium Medical had no role in the study design, data collection, data interpretation, or writing of the clinical report.  Atrium provided funding for the study, including the employment of a research assistant.

Dr. Mwipatayi has provided this statement regarding COBEST: "This was the first prospective, randomized, multi center, controlled trial comparing balloon expandable covered stents directly to bare metal stents.  One striking result from the COBEST study was the 5 times lower TVR rate with Atrium's V12 compared to BMS.  This poses a tremendous global economic benefit along with a tremendous quality of life benefit for our patients who are being treated for peripheral vascular disease and more specifically aorto-iliac disease."

About Atrium's Advanta™ V12 covered stent

The Advanta™ Vascular V12 covered stent is a low profile, pre-mounted covered stent made of a radial expandable stainless steel that is completely encapsulated with Atrium's patented one-piece covering technology.  Atrium's patented covering technology creates a thermoconformable microporous PTFE layer that completely encapsulates the stainless steel stent.

Covered stents have been shown to exclude plaque and endothelium, thereby potentially mitigating late luminal loss by halting migration and proliferation of vascular smooth muscle cells and inflammatory cells through open stent struts thus leading to a reduction in restenosis and occlusion rates.  With over 125 clinical publications and over 100,000 patients successfully treated worldwide, this latest publication adds to the rapidly growing body of evidence supporting the safety and efficacy of Atrium's covered stent technology.  The V12 covered stent is CE approved for restoring the patency of iliac and renal vessels and is available in diameters of 5mm to 16mm. The Advanta™ V12 covered stent is not available in the United States.    http://www.atriummed.com/AdvantaV12

About Peripheral Arterial Disease (PAD)

Peripheral Arterial Disease affects over 100 Million people worldwide.  Patients with PAD typically present with symptoms known as claudication or rest pain.  Claudication is severe pain and discomfort or cramping in the legs that occurs when walking or exercising.  Rest pain is defined as "continued pain" or "painful cramping" of the legs immediately following exercise or when a patient is resting.  This lower extremity leg pain is often caused by decreased blood flow to areas of the leg caused by a narrowing of major blood vessels, often as a result of atherosclerosis (build-up of plaque and cholesterol) along the luminal walls of peripheral arteries, including the iliac, femoral and popliteal vessels.

About Atrium Medical

Atrium's vast expertise in medical device technologies for the treatment of vascular and coronary disease, chest trauma, hernia and soft tissue injury has brought a number of breakthrough advances in several diversified healthcare markets. Maintaining a commitment to the latest ISO 13485 Quality Standards, state-of-the-art manufacturing and automation, cell biology and biomaterial discovery programs, Atrium continues to excel in those healthcare segments that require more advanced minimally invasive and surgical intervention options for improvements in patient outcomes. For more information please call Atrium's Marketing Communications Department at 1-800-370-7899 or visit us on the web at www.atriummed.com .


'/>"/>
SOURCE Atrium Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
2. Atrium Responds to Bard Suit
3. Atrium Recognized by Business NH Magazine
4. Atrium Recognized by New Hampshire Bio/Medical Council
5. Atrium and Kaneka Launch Xpress-Way™ RX Extraction Catheter in the U.S.
6. Atrium Provides Grant to Establish Education Web Site at AtriumU.com
7. Atrium Honored by the Premier Healthcare Alliance for Operational Excellence
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , Feb. 9, 2016  The Parenteral Drug ... professionals developing and manufacturing sterile drug products, today ... Regulatory Guidance Comparison – With link to Comparison ... issued by the U.S. FDA, the EU, the ... --> --> ...
(Date:2/8/2016)... LONDON , Feb.8, 2016 Respiratory ... Summary GlobalData,s Medical Devices sector report, " ... " provides an overview of Respiratory Devices currently ... information on the pipeline products with comparative analysis ... The report reviews major players involved in the ...
(Date:2/8/2016)... NEW YORK , Feb. 8, 2016 /PRNewswire/ ... market, today announces its first male sexual enhancement ... enhancement, EnduramenT combines proven ethnobotanicals with a patented ... of nitric oxide, the chemical compound responsible for ... Forgoing the ...
Breaking Medicine Technology:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... Mammal Prize has officially been won. A team from 21st Century Medicine (21CM) ... a way to preserve the delicate neural circuits of an intact rabbit brain ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... Nutrition into the Food & Beverage and Dietary Supplement ... partner throughout Canada and USA geographies east of the Rocky Mountains since 2012. ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Valentine’s Season is famous for gift giving with flowers, chocolates ... they are loved. This year, for more than 5.6 million Americans suffering with Alzheimer’s, ... be enough to remind them of the lives they’ve led and the people they’ve touched. ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that your clothes are ... alone. According to the Center for Disease Control and Prevention (CDC), 34.9% of U.S. ... certain types of cancer, some of the leading causes of preventable death. February ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Bell Agency, a full ... beneficiary of their ongoing community enrichment program. The current campaign fundraises for Angels ... are now being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves was ...
Breaking Medicine News(10 mins):